More than five years after the launch of Switzerland’s Covid-19 vaccination campaign, the Confederation has awarded two individuals financial compensation for damages believed to be linked to the vaccine. This marks a significant development in the ongoing process of evaluating claims related to adverse effects following vaccination, with a total of 408 requests having been submitted to date. The first compensation, approved in 2024, involved a payment of 12,500 Swiss francs for damages plus an additional 1,360 francs as an indemnity. This initial payout signals a willingness to address legitimate cases of harm, while also acknowledging the complexities of establishing a causal link between vaccination and health issues.
The decision to provide these indemnisations comes after careful consideration by the Confederation, with the process often taking years from initial claim to final resolution. Establishing a direct causal link between the Covid-19 vaccine and reported health problems is a crucial requirement for receiving compensation. This evaluation is conducted by the Federal Office of Public Health (OFSP). According to the Department of Federal Interior (DFI), approximately 50 claims are currently pending, with 30 undergoing detailed examination. The Confederation has received 320 requests for compensation overall.
Establishing Causation and the Indemnification Process
The Swiss system for compensating individuals experiencing adverse effects from the Covid-19 vaccine hinges on demonstrating a clear connection between the vaccination and the health issue. The OFSP plays a central role in assessing this potential link. The DFI confirmed to Sonntagsblick that the first person to receive compensation was able to demonstrate a loss of income due to their condition. This suggests that financial repercussions resulting from vaccine-related health problems are a key factor in the approval process. The awarded sum is considered a form of reparation for the documented loss.
The majority of reported suspected cases involve the Moderna vaccine, which was the most widely used vaccine in Switzerland during the campaign. The right to compensation is predicated on the fact that the vaccination was recommended by the Confederation. The state acts as a payer of last resort, stepping in only when insurance providers or the vaccine manufacturer refuse to cover the costs. Swissmedic, the Swiss agency for therapeutic products, has not yet identified any confirmed defects in the vaccine doses administered.
Limited Compensation to Date and Ongoing Claims
While two individuals have now received compensation, the number remains tiny relative to the total number of vaccinations administered in Switzerland. The Confederation cannot seek recourse from the vaccine manufacturer unless a proven defect in the vaccine is identified. This highlights the challenges in attributing specific health problems directly to the vaccine and the high bar for establishing causality. The first instance of compensation was reported by RTS in February 2024.
The process of evaluating claims is expected to continue for some time, as the long-term effects of the Covid-19 vaccine are still being studied. The DFI has indicated that it may take years between the submission of a claim and the final decision on compensation. This lengthy timeline underscores the complexity of assessing the potential link between vaccination and health issues, and the need for thorough investigation.
What This Means for Those Affected
These initial compensations offer a degree of relief for those who believe they have experienced harm as a result of the Covid-19 vaccine. But, the stringent requirements for establishing causality mean that many claims may ultimately be denied. Individuals who believe they have suffered adverse effects are encouraged to gather comprehensive medical documentation and submit their claims through the appropriate channels. The Confederation provides information on the process through the OFSP website.
The situation in Switzerland mirrors similar debates and legal challenges occurring in other countries regarding vaccine-related injuries and compensation. The need for transparent and equitable processes for evaluating claims and providing support to those affected remains a critical issue as the world continues to grapple with the long-term consequences of the Covid-19 pandemic. The La Côte reported on February 14, 2026, that the two indemnisations were awarded more than five years after the launch of the vaccination campaign.
The Confederation will continue to assess claims as they are submitted, and further updates on the process will be provided as they turn into available. The next scheduled update from the DFI regarding the compensation program is expected in the spring of 2026.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical or legal advice. It is essential to consult with a qualified healthcare professional or legal expert for any health concerns or legal questions.
What are your thoughts on the Swiss Confederation’s decision to provide compensation for vaccine-related injuries? Share your comments below, and please share this article with your network.
